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We describe a case of HIV/tuberculosis (TB) co-infection from KwaZulu-Natal, South Africa, characterised by drug resistance 
in both pathogens. The development of drug resistance was linked temporally to two periods of incarceration. This highlights 
the urgent need for improved integration of HIV/TB control strategies within prison health systems and within the broader 
public health framework. 
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The twin epidemics of HIV and tuberculosis 
(TB) have had a devastating impact on 
individuals, families and communities in South 
Africa (SA) over the past two decades.[1] SA 
alone is responsible for almost one-third of the 
global burden of HIV-associated TB.[2] While much progress 
has been made in the last few years with robust responses to 
these epidemics, many challenges remain.[3] Antiretroviral and 
anti-TB drug resistance pose considerable threats to the control 
of these epidemics.[4,5] The breakdown in HIV/TB control 
within prisons is another emerging threat.[6,7] We describe one 
of the first reports of combined antiretroviral and anti-TB drug 
resistance, where the development of resistance was closely 
associated with two periods of incarceration.     
Case report
A 34-year-old unemployed male presented to a primary 
healthcare (PHC) clinic in Hlabisa sub-district, KwaZulu-
Natal, in February 2012 with a cough, night sweats and weight 
loss. He had been diagnosed with HIV infection in 2002, but 
had not accessed HIV care until April 2009 when he presented 
with his first episode of smear-negative pulmonary TB. At that 
time, his CD4+ cell count was 85 cells/µl and he was initiated 
on a standard first-line antiretroviral therapy (ART) regimen 
of stavudine (d4T), lamivudine (3TC), and efavirenz (EFV). He 
achieved complete virological suppression (HIV viral load <50 
copies/ml) and a good immunological response (CD4+ count 
482 cells/µl) after 5 months of ART (Fig. 1). In May 2010, he 
was incarcerated (in a correctional facility approximately 50 km 
from home) and as a result of non-disclosure of HIV status to 
prison officials, his ART was interrupted. Following release in 
September 2010, he had re-engaged with care at the PHC clinic 
and had been restarted on ART (tenofovir (TDF), 3TC and 
EFV). Within 6 months, he was once again detained in prison 
and his ART was interrupted once again for several months. 
He reported that he shared a cell with up to 50 people during 
this second spell in prison, several of whom were coughing and 
one had apparently stated that he had multidrug-resistant TB 
(MDR-TB). 
Xpert® MTB/RIF was performed on sputum and detected 
Myco bacterium tuberculosis resistant to rifampicin. He was 
referred to the provincial drug-resistant TB unit (approximately 
250 km from home) and was commenced on a standardised 
regimen of kanamycin, moxifloxacin, ethionamide, terizidone, 
pyrazinamide and isoniazid. Two weeks later, he was re-initiated 
on ART (TDF, 3TC and EFV). He completed the intensive 
phase of drug-resistant TB treatment with a good treatment 
response (acid-fast bacilli smear and culture negative after 
2 months) and no evidence of nephrotoxicity, but there was 
no virological response to ART (viral load 390 845 copies/ ml 
6 months after restarting ART), despite documented good 
adherence. 
Genotypic resistance testing was performed and revealed 
non-nucleoside reverse transcriptase inhibitor (NNRTI) 
resistance mutations (K103N and V106M) and nucleoside 
reverse transcriptase inhibitor (NRTI) resistance mutations 
(K65R and M184V), conferring high-level resistance to EFV 
and 3TC, and intermediate-level resistance to TDF. Hepatitis 
B surface antigen (HBsAg) was negative and haemoglobin was 
12.7 g/dl. As a result, he was switched to a second-line ART 
regimen consisting of co-formulated zidovudine (AZT) and 
3TC with lopinavir/ritonavir (LPV/r). At this stage, the total 
number of pills taken daily was 27 (including co-trimoxazole 
and pyridoxine). As of June 2013, he continues to be followed 
up at his local PHC clinic (2 km from home) and at the drug-
resistant TB unit. 
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Consent
Written informed consent was given by the patient prior to publication.
Discussion
The issue of TB control in SA prisons has recently received much 
attention, as a result of the successful legal action against the Minister 
of Correctional Services by a former prison inmate who contracted TB 
while in a correctional facility awaiting trial.[8] Here we have described 
a case where acquisition of drug-resistant TB most likely occurred 
in prison and the clinical course was compounded by the emergence 
of antiretroviral drug resistance. This has significance, not only for 
individual health, with increased treatment complexity and adverse 
clinical outcomes, but also for the health of the wider community, with 
the risk of onward transmission of drug-resistant infections. The case 
here highlights the need for an improved and more integrated approach 
to HIV/TB prevention and care in prisons, as well as better linkage 
between prison health services and the public health system. 
The incidence of TB disease in prisons worldwide has been shown to 
be more than 20 times that of the general population.[9] This is widely 
attributed to factors such as overcrowding, poor nutrition, insufficient 
ventilation and inadequate health services in prisons.[7,10-12] The problem 
is amplified in countries with a high HIV burden, as HIV infection 
is the strongest individual risk factor for developing active TB.[12-14] 
HIV prevalence is also often higher than that among the general 
population, with estimates of 40 - 45% in SA prisons.[15,16] Only 40% of 
SA correctional centres report segregating inmates on medical grounds, 
although drug-resistant TB has been cited as the most common reason 
for such segregation.[17] Ventilation is frequently poor;[6,11] our patient 
described small, slit-like windows high up on one exterior wall of his 
cell. There is a shortage of medical personnel in prisons and delays 
in accessing care are frequently an issue;[6,8,11,17] our patient stated that, 
during his second period of detention, he had reported his cough and 
night sweats to prison officials for 3 weeks before he was taken to the 
prison health facility.
The epidemiology of communicable diseases within and outside 
prisons is closely related; large numbers of prisoners and staff enter 
and leave prisons on a daily basis, acting as potential sources of 
transmission to the community at large. In SA in 2011/ 2012, over 80% 
of remand detainees[17] and 40% of those who received sentences were 
imprisoned for less than one year.[18] Thus, in SA, as elsewhere, prisons 
act as reservoirs of TB, and inevitably drug-resistant TB, that poses a 
threat to public health control.[12,14] Despite this, control measures for 
TB, HIV and other communicable diseases are often neglected, relative 
to measures directed at non-prison populations.[19]
Many of the same factors that enhance the spread of TB in prisons 
encourage the emergence of drug resistance and subsequent transmission 
of drug-resistant TB.[10,19] Moreover, the failure to ensure prompt 
recognition and appropriate treatment of drug-resistant cases results in 
a prolonged infective period, such that transmission risks may be even 
higher than those associated with drug-susceptible TB.[11] There are 
additional factors that may particularly promote the development of 
drug-resistant TB in prisons, such as: erratic drug supply and inadequate 
treatment; access to uncontrolled anti-TB drugs from staff and visitors; 
and chaotic lifestyles, including transfers between and within prisons. 
These enhance the likelihood of treatment interruption or default.[19] 
While there is a paucity of data on antiretroviral drug resistance in 
prison populations, HIV-positive prisoners receiving ART in Brazil 
have been found to have high rates of acquired HIV drug resistance;[20] 
and release from prison followed by re-incarceration has been shown to 
be associated with impaired virological and immunological outcomes 
while receiving ART.[21] Unplanned treatment interruptions are 
known to promote resistance;[22-24] and chaotic lifestyles,[18,19] fear of 
stigmatisation[18,25] and poor health services in prisons[6,25] are likely 
to increase the frequency of treatment interruptions. In SA, most 
prisons do not have dedicated HIV care programmes and those that 
exist are delivered by external service providers.[17] Our patient did 
not disclose his HIV-positive status or use of ART during either spell 
in prison, primarily due to fear of stigmatisation. While the timing 
of the development of ART drug resistance cannot be ascertained 
definitively in this case, it is plausible that the unscheduled interruption 
of treatment during the first period of incarceration could have led to 
the initial emergence of resistance. Certainly the interruption of ART, 
the emergence of ART drug resistance and the resultant drop in CD4+ 
cell count would have substantially increased the risk of developing 
TB disease.[26] We cannot definitively reject the possibility that ART 
resistance emerged prior to incarceration or that super-infection with a 
drug-resistant HIV strain occurred during incarceration.  
The interdependence of numerous transmission risk factors necessitates 
a multifaceted approach to TB control in prisons, involving improvement 
in case finding, reductions in overcrowding and improvements in 
environmental conditions such as ventilation and airflow.[6,10-12,14] Robust 
evidence for action already exists: a modelling analysis based on 
conditions for inmates awaiting trial in Pollsmoor prison, Cape Town, 
suggested a potential reduction in TB transmission rates of 50% if active 
case finding and national minimum standards of cell occupancy were 
implemented; and a reduction of 94% if international environmental 
standards were adopted.[11] Screening and case detection in prisons 
worldwide has, until recently, been limited by suboptimal diagnostic tools 
and a lack of adequate laboratory facilities. [27] There is some evidence to 
suggest that screening prisoners using Xpert MTB/RIF could be a cost-
effective means to reduce transmission of drug-resistant TB in settings 
with a high burden of drug resistance.[28] The recent announcement that 
correctional facilities in SA will now be prioritised for deployment of 
Xpert MTB/RIF offers strong encouragement.[29] However, research is 
needed to inform policies on the optimal use of Xpert MTB/RIF within 
prison health services, and any strategy must be linked to appropriate 
treatment programmes and proper segregation processes.
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Fig. 1. Clinical course of ART with results of viral load (VL) and CD4+ cell count 
monitoring and timing of treatment interruptions.
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Furthermore, this case highlights that reducing the individual risk of TB 
disease should be as important, and optimising individual management 
of HIV disease, with the aim of virological suppression and prevention 
of antiretroviral resistance, should be a critical component of broader 
prison HIV/TB control strategies. No single intervention will adequately 
address the complex issues relating to TB and HIV in prisons. 
Ultimately, there needs to be the political will and funding to deliver 
sustained improvements to prison conditions and health services. 
Collaboration between the Department of Correctional Services and 
the Department of Health is necessary to facilitate better integration of 
prison health services within the public health system. The high costs 
of managing drug-resistant TB and HIV disease should be a powerful 
incentive to implement measures to reduce the emergence and spread 
of drug-resistant TB and HIV.[30-32] At a time when considerable progress 
is being made in the public health sector in SA,[3] the failure to address 
TB and HIV in prisons has the potential to seriously undermine the 
control of these infectious diseases in the community.
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